Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part Open Label Study of the Pharmacodynamic Effects of Intranasal Nalmefene Compared to Intranasal Naloxone in Healthy Volunteers Under Steady State Opioid Agonism

NCT04828005 is registered in ClinicalTrials.gov with Opiant Pharmaceuticals Inc as lead sponsor.

NCT NCT04828005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04828005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part Open Label Study of the Pharmacodynamic Effects of Intranasal Nalmefene Compared to Intranasal Naloxone in Healthy Volunteers Under Steady State Opioid Agonism
Lead sponsor
Opiant Pharmaceuticals Inc
Phase
Phase 1
Overall status
Completed
Start date
March 30, 2021
Completion date
March 14, 2022
Enrollment
84 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pharmacodynamic